VISTA expression and patient selection for immune-based anticancer therapy
Martin, Alexander S, Molloy, Michael, Ugolkov, Andrey, von Roemeling, Reinhard W, Noelle, Randolph J, Lewis, Lionel D, Johnson, Melissa, Radvanyi, Laszlo, Martell, Robert E
Published in Frontiers in immunology (20.02.2023)
Published in Frontiers in immunology (20.02.2023)
Get full text
Journal Article
Preliminary safety, efficacy and molecular characterization of emavusertib (CA-4948) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) with FLT3 mutation (FLT3m)
Winer, Eric S., Verma, Amit, Groepper, Stefanie, Gotze, Katharina S., Abaza, Yasmin, Mikesch, Jan-Henrik, Choudhary, Gaurav S, Masciarelli, Alyssa, Zhao, Wanying, Gallagher, Cole, Von Roemeling, Reinhard W., DeAngelo, Daniel J.
Published in Journal of clinical oncology (01.06.2024)
Published in Journal of clinical oncology (01.06.2024)
Get full text
Journal Article
Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors
Shulman, Lawrence N, Buswell, Lori, Riese, Nancy, Doherty, Nancy, Loeffler, Jay S, von Roemeling, Reinhard W, Coleman, C.Norman
Published in International journal of radiation oncology, biology, physics (01.05.1999)
Published in International journal of radiation oncology, biology, physics (01.05.1999)
Get full text
Journal Article
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies
Joffe, Erel, Nowakowski, Grzegorz S., Tun, Han W., Rosenthal, Allison Claire, Lunning, Matthew Alexander, Ramchandren, Radhakrishnan, Li, Chia-Cheng, Zhou, Li, Martinez, Elizabeth, Von Roemeling, Reinhard W., Earhart, Robert H., McMahon, Meaghan, Isufi, Iris, Leslie, Lori Ann
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Phase 1/2a study of the IRAK4 inhibitor CA-4948 as monotherapy or in combination with azacitidine or venetoclax in patients with relapsed/refractory (R/R) acute myeloid leukemia or lyelodysplastic syndrome
Garcia-Manero, Guillermo, Winer, Eric S., DeAngelo, Daniel J., Tarantolo, Stefano R., Sallman, David Andrew, Dugan, James, Groepper, Stefanie, Giagounidis, Aristoteles, Gotze, Katharina S., Metzeler, Klaus, Li, Chia-Cheng, Zhou, Li, Martinez, Elizabeth, Lane, Maureen E, Von Roemeling, Reinhard W., Bohme, Matthias, Kubasch, Anne Sophie, Verma, Amit K., Platzbecker, Uwe
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Abstract 2902: CA-4948 (emavusertib) improves treatment response of preclinical metastatic brain melanoma to anti-PD-1 immune checkpoint blockade
von Roemeling, Christina A., Doonan, Bently P., Acevedo, Amanda M., Patel, Jeet A., Carpenter, Savannah L., Bhatia, Alisha, von Roemeling, Reinhard W., Hoffman, Jamison, Lane, Maureen, Mitchell, Duane A.
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Published in Cancer research (Chicago, Ill.) (22.03.2024)
Get full text
Journal Article
Abstract LB203: Targeted inhibition of IRAK-4 with CA-4948 (emavusertib) sensitizes metastatic brain melanoma to anti-PD-1 immune checkpoint blockade
von Roemeling, Christina A., Doonan, Bently P., Russell, Rylynn A., Elliott, Tyler V., Matich, Erica, Archibald, Vincent, Hoang-Minh, Lan, von Roemeling, Reinhard W., Ferrari, Dora, Hoffman, Jamison, Mitchell, Duane A.
Published in Cancer research (Chicago, Ill.) (14.04.2023)
Published in Cancer research (Chicago, Ill.) (14.04.2023)
Get full text
Journal Article
Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC)
Rimassa, Lorenza, Abbadessa, Giovanni, Personeni, Nicola, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Van Laethem, Jean-Luc, Van Vlieberghe, Hans, Trojan, Jorg, de Toni, Enrico, Peck-Radosavljevic, Markus, Finn, Richard S., Raoul, Jean-Luc, He, Aiwu Ruth, Lamar, Maria, Wang, Yunxia, Von Roemeling, Reinhard W., Schwartz, Brian E., Bruix, Jordi, Santoro, Armando
Published in Journal of clinical oncology (01.02.2016)
Published in Journal of clinical oncology (01.02.2016)
Get full text
Journal Article
A randomized, open-label phase II study of efatutazone in combination with FOLFIRI as second-line therapy for metastatic colorectal cancer (mCRC)
Marshall, John, Shuster, Dale Edward, Goldberg, Terri Robin, Copigneaux, Catherine, Chen, Shuquan, Zahir, Hamim, Dutta, Dipen, Saleh, Mansoor N., Pishvaian, Michael J., Varela, Mirta Susana, Palazzo, Felipe, Lazaretti, Nicolas, Costa, Cassia, Loredo, Eugenia, Leon, Jorge, Von Roemeling, Reinhard W.
Published in Journal of clinical oncology (20.01.2014)
Published in Journal of clinical oncology (20.01.2014)
Get full text
Journal Article
Intravesical recombinant tumor necrosis factor in the treatment of superficial bladder cancer: an Eastern Cooperative Oncology Group study
Glazier, D B, Bahnson, R R, McLeod, D G, von Roemeling, R W, Messing, E M, Ernstoff, M S
Published in The Journal of urology (01.07.1995)
Published in The Journal of urology (01.07.1995)
Get more information
Journal Article
Metabolic characterization of human soft tissue sarcomas in vivo and in vitro using proton-decoupled phosphorus magnetic resonance spectroscopy
LI, C.-W, KUESEL, A. C, PADAVIC-SHALLER, K. A, MURPHY-BOESCH, J, EISENBERG, B. L, SCHMIDT, R. G, VON ROEMELING, R. W, PATCHEFSKY, A. S, BROWN, T. R, NEGENDANK, W. G
Published in Cancer research (Chicago, Ill.) (01.07.1996)
Get full text
Published in Cancer research (Chicago, Ill.) (01.07.1996)
Journal Article